These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10905488)

  • 1. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp.
    Carroll PV; Christ ER; Umpleby AM; Gowrie I; Jackson N; Bowes SB; Hovorka R; Croos P; Sönksen PH; Russell-Jones DL
    Diabetes; 2000 May; 49(5):789-96. PubMed ID: 10905488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.
    Simpson HL; Jackson NC; Shojaee-Moradie F; Jones RH; Russell-Jones DL; Sönksen PH; Dunger DB; Umpleby AM
    J Clin Endocrinol Metab; 2004 Jan; 89(1):425-32. PubMed ID: 14715881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of insulin and amino acids on leucine metabolism in young and middle-aged humans.
    Luzi L; Giordano M; Caloni ; Castellino P
    Eur J Nutr; 2001 Jun; 40(3):106-12. PubMed ID: 11697442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
    Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM.
    Carroll PV; Umpleby M; Ward GS; Imuere S; Alexander E; Dunger D; Sönksen PH; Russell-Jones DL
    Diabetes; 1997 Sep; 46(9):1453-8. PubMed ID: 9287046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humans.
    Oehri M; Ninnis R; Girard J; Frey FJ; Keller U
    Am J Physiol; 1996 Apr; 270(4 Pt 1):E552-8. PubMed ID: 8928758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low plasma insulin-like growth factor-1 concentrations predict worsening of insulin-mediated glucose uptake in older people.
    Paolisso G; Tagliamonte MR; Rizzo MR; Carella C; Gambardella A; Barbieri M; Varricchio M
    J Am Geriatr Soc; 1999 Nov; 47(11):1312-8. PubMed ID: 10573439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five weeks of insulin-like growth factor-I treatment does not alter glucose kinetics or insulin sensitivity during a hyperglycemic clamp in older women.
    Braun B; Friedlander AL; Pollack M; Butterfield GE; Marcus R; Hoffman AR
    Metabolism; 2003 Sep; 52(9):1182-90. PubMed ID: 14506625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism.
    Tessari P; Nosadini R; Trevisan R; De Kreutzenberg SV; Inchiostro S; Duner E; Biolo G; Marescotti MC; Tiengo A; Crepaldi G
    J Clin Invest; 1986 Jun; 77(6):1797-804. PubMed ID: 3519679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.
    Moller L; Norrelund H; Jessen N; Flyvbjerg A; Pedersen SB; Gaylinn BD; Liu J; Thorner MO; Moller N; Lunde Jorgensen JO
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4524-32. PubMed ID: 19820031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone signaling and action in obese versus lean human subjects.
    Høgild ML; Bak AM; Pedersen SB; Rungby J; Frystyk J; Møller N; Jessen N; Jørgensen JOL
    Am J Physiol Endocrinol Metab; 2019 Feb; 316(2):E333-E344. PubMed ID: 30576246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.